The p75NTR metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells

Clinical and Experimental Metastasis

Volumn 23, Issue 2, 2006, Pages 107-116

  Nalbandian, Angèle ^a   Djakiew, Daniel ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Metastasis suppressor; MMP 2; MMP 9; p75NTR; Prostate cancer; TIMP 1; uPA

Indexed keywords

GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; NEUROTROPHIN RECEPTOR; P75 NEUROTROPHIN RECEPTOR; PROTEIN P75; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; METASTASIS; METASTASIS INHIBITION; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ZYMOGRAPHY;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NERVE TISSUE PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, NERVE GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; URINARY PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 33748967964     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-006-9009-y     Document Type: Article

References (48)

1. American Cancer Society. Cancer facts & figures. American Cancer Society, Inc. www.cancer.org 2006; 4-6
2. Krygier S, Djakiew D (2002) Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 98:1-7
3. Krygier S, Djakiew D (2001) The neurotrophin receptor p75NTR is a tumor suppressor in human prostate cancer. Anticancer Res 21:3749-3755
4. Nalbandian A, Pang AL, Rennert OM, Chan WY, Ravindranath N, Djakiew DA (2005) A novel function of differentiation revealed by cDNA microarray profiling of p75-regulated gene expression. Differentiation 73:385-396
5. Allen J, Khwaja F, Byers S, Djakiew D (2005) The p75(NTR) mediates a bifurcated signal transduction cascade through the NFkappaB and JNK pathways to inhibit cell survival. Exp Cell Res 304:69-80
6. Allen J, Khwaja F, Djakiew D (2004) Gene therapy of prostate xenograft tumors with a p75NTR lipoplex. Anticancer Res 24:2997-3003
7. Sheng S (2001) The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 20:287-296
8. Gondi CS, Lakka SS, Yanamandra N, Siddique K, Dinh DH, Olivero WC, Gujrati M, Rao JS (2003) Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 22:5967-5975
9. Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S (1999) Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 14:535-541
10. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25-40
11. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M (1998) Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 13:893-906
12. Rabbani SA, Mazar AP (2001) The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 10:393-415, x
13. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, Korc M, Buchler MW (1997) Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75:388-395
14. Moller JV, Le MM (1993) Detergent binding as a measure of hydrophobic surface area of integral membrane proteins. J Biol Chem 268:18659-18672
15. Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541-573
16. Bjorklund M, Koivunen E (2005) Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755:37-69
17. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839
18. John A, Tuszynski G (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7:14-23
19. Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG (1997) Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging 11:229-244
20. Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270
21. Gohji K, Fujimoto N, Hara I, Fujii A, Gotoh A, Okada H, Arakawa S, Kitazawa S, Miyake H, Kamidono S, Nakajima M (1998) Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 79:96-101
22. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR (1998) Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58:1395-1399
23. Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267-283
24. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74:111-122
25. Henriet P, Blavier L, Declerck YA (1999) Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 107:111-119
26. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG (1991) Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83:775-779
27. Declerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM (1992) Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52:701-708
28. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, Denhardt DT (1989) Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 243:947-950
29. Krygier S, Djakiew D (2001) Molecular characterization of the loss of p75(NTR) expression in human prostate tumor cells. Mol Carcinog 31:46-55
30. Solomon A, Li DQ, Lee SB, Tseng SC (2000) Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. Invest Ophthalmol Vis Sci 41:2154-2163
31. Kleiner DE, Stetler-Stevenson WG (1994) Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218:325-329
32. Wang X, Bauer JH, Li Y, Shao Z, Zetoune FS, Cattaneo E, Vincenz C (2001) Characterization of a p75(NTR) apoptotic signaling pathway using a novel cellular model. J Biol Chem 276:33812-33820
33. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, Mackay AR (1998) Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 75:721-730
34. Alfano D, Franco P, Vocca I, Gambi N, Pisa V, Mancini A, Caputi M, Carriero MV, Iaccarino I, Stoppelli MP (2005) The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 93:205-211
35. Djakiew D, Pflug BR, Delsite R, Onoda M, Lynch JH, Arand G, Thompson EW (1993) Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. Cancer Res 53:1416-1420
36. Khwaja F, Tabassum A, Allen J, Djakiew D (2006) The p75(NTR) tumor suppressor induces cell cycle arrest facilitating caspase mediated apoptosis in prostate tumor cells. Biochem Biophys Res Commun 341:1184-1192
37. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S, Mignatti P (1997) Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16:2319-2332
38. Stearns ME, Fudge K, Garcia F, Wang M (1997) IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis 17:62-74
39. Stearns ME, Rhim J, Wang M (1999) Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 5:189-196
40. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA Jr, Kallakury BV (2003) Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16:198-205
41. Stearns ME, Stearns M (1996) Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer. Oncol Res 8:63-67
42. Still K, Robson CN, Autzen P, Robinson MC, Hamdy FC (2000) Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 42:18-25
43. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ, Cher ML (1999) Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 5:4105-4110
44. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME (1997) In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 15:246-258
45. Sottrup-Jensen L, Birkedal-Hansen H (1989) Human fibroblast collagenase-alpha-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins. J Biol Chem 264:393-401
46. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174
47. Olson MW, Gervasi DC, Mobashery S, Fridman R (1997) Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem 272:29975-29983
48. Perez M, Regan T, Pflug B, Lynch J, Djakiew D (1997) Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 30:274-279